Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KRINTAFEL vs ARAKODA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
KRINTAFEL (tafenoquine) is an 8-aminoquinoline antimalarial that inhibits parasite growth by interfering with the electron transport chain in the mitochondria of Plasmodium species. It is active against both the erythrocytic and exoerythrocytic stages, including hypnozoites of P. vivax.
ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.
For the radical cure of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection
Radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection
Adults: 200 mg orally as a single dose.
400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).
Terminal elimination half-life is approximately 5-7 days in healthy subjects. Due to accumulation, steady state is achieved after 4-5 weeks of weekly dosing. In patients with renal impairment, half-life may be prolonged.
Terminal elimination half-life: approximately 14-16 days (range 12-19 days) in healthy adults; this long half-life is due to extensive tissue distribution and slow release from tissues, providing prophylactic coverage for up to 4 weeks after a single dose.
Primarily metabolized via CYP2D6 to an active metabolite. Tafenoquine itself may also be metabolized by monoamine oxidase (MAO).
Primarily metabolized by CYP2D6 and monoamine oxidase (MAO). Tafenoquine undergoes extensive metabolism including N-dealkylation and oxidation.
Primarily renal; approximately 70-80% of administered dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Fecal excretion accounts for less than 5%.
Biliary/fecal: ~90% unchanged; renal: <1% unchanged (dose-proportional urinary excretion of tafenoquine is minimal, with most eliminated via feces as unchanged drug and minor metabolites).
≥99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
~99.5% bound to human serum albumin (HSA); binding is high and saturable, with unbound fraction slightly increasing at high concentrations.
Approximately 10-15 L/kg, indicating extensive tissue distribution and binding to haemoglobin in red blood cells.
Apparent Vd: ~2000 L (or ~24-30 L/kg based on 70 kg), indicating extensive tissue distribution (concentrated in red blood cells, liver, lungs, and adipose tissue).
Oral bioavailability is approximately 70-80% under fasting conditions. Food may slightly increase or decrease absorption; however, the label recommends administration with or without food.
Oral: ~100% (absolute bioavailability not formally determined, but absorption is complete with minimal first-pass metabolism; relative bioavailability is high based on AUC and clinical efficacy).
No adjustment needed for mild to moderate renal impairment (e GFR >=30 m L/min). Not studied in severe renal impairment (e GFR <30 m L/min) or on dialysis; use caution.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No adjustment for mild Child-Pugh A. Not recommended in moderate (Child-Pugh B) or severe (Child-Pugh C) due to lack of data.
Contraindicated in Child-Pugh Class B or C. Use with caution in mild hepatic impairment (Child-Pugh Class A) with no dose adjustment.
Children ≥5 years and ≥15 kg: 6 mg/kg (maximum 200 mg) as a single oral dose. Not established for <5 years or <15 kg.
Safety and efficacy not established in pediatric patients (<18 years).
No specific adjustment; use standard dose with monitoring for adverse effects due to potential age-related renal/hepatic decline.
No specific dose adjustment; use with monitoring for renal function due to age-related decline and potential for increased adverse effects.
Warning: G6PD deficiency – can cause hemolytic anemia in G6PD-deficient individuals. Test for G6PD deficiency before prescribing. Do not use in G6PD-deficient patients.
ARAKODA can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD testing must be performed before prescribing due to risk of hemolytic anemia.
Hemolytic anemia in G6PD-deficient patients: screen all patients for G6PD deficiency before use.,Methemoglobinemia: monitor for signs; use with caution in patients with NADH-methemoglobin reductase deficiency.,Psychiatric effects: may cause anxiety, depression, or psychosis; use with caution in patients with psychiatric disorders.,Prolonged QT interval: avoid in patients with cardiac conditions or those taking other QT-prolonging drugs.,Hematologic monitoring: monitor CBC during treatment.
Hemolytic anemia in G6PD-deficient patients (contraindicated in G6PD deficiency without prior testing),Methemoglobinemia (rare, monitor for cyanosis and dyspnea),Psychiatric effects including anxiety, depression, and insomnia,Hepatotoxicity (rare, monitor liver function),Use in pregnancy: not recommended (risk of hemolysis in G6PD-deficient fetus),Lactation: avoid if breastfeeding infant is G6PD deficient
G6PD deficiency (absolute),History of psychotic disorder (absolute),Breastfeeding (relative; avoid unless infant G6PD normal),Pregnancy (relative; avoid unless benefit outweighs risk)
G6PD deficiency (without confirmed normal G6PD activity),Known hypersensitivity to tafenoquine or any 8-aminoquinoline,Use in children <16 years (safety not established),Severe renal impairment (e GFR <30 m L/min),Lactation in infants with G6PD deficiency or unknown G6PD status
Take with food (preferably a fatty meal) to enhance absorption and reduce gastrointestinal side effects. Avoid grapefruit and grapefruit juice as they may alter drug metabolism. No other specific dietary restrictions.
Take with a fatty meal to increase absorption. No specific dietary restrictions. Avoid grapefruit juice as it may alter metabolism.
No human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if benefit outweighs risk.
FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.
No data on human milk excretion; M/P ratio unknown. Risk to infant cannot be ruled out; consider stopping breastfeeding due to potential adverse effects.
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in infant; use caution, consider discontinuing breastfeeding.
No dose adjustment recommended; pharmacokinetics in pregnancy not studied. Maintain standard dose but use only if clearly needed.
No established dose adjustments; pharmacokinetic changes in pregnancy may require monitoring drug levels and clinical response.
KRINTAFEL (tafenoquine) is indicated for radical cure of Plasmodium vivax malaria. Administer with food to improve absorption and reduce gastrointestinal intolerance. Screen patients for G6PD deficiency before use; contraindicated in G6PD-deficient patients due to risk of hemolytic anemia. Monitor for methemoglobinemia, especially in patients with NADH-methemoglobin reductase deficiency. Avoid in pregnancy and lactation unless benefit outweighs risk. Single-dose regimen improves adherence compared to primaquine.
ARAKODA (tafenoquine) is indicated for radical cure of Plasmodium vivax malaria. Assess G6PD status before prescribing; contraindicated in G6PD-deficient patients due to hemolytic anemia risk. Monitor for methemoglobinemia. Avoid use in pregnancy/lactation. Take with food to enhance absorption.
Take this medication exactly as prescribed, usually as a single dose with food to reduce stomach upset.,You must be tested for G6PD deficiency before starting this medication; inform your doctor if you have a history of anemia or enzyme deficiency.,Avoid alcohol during treatment as it may increase risk of side effects.,Report any signs of dark urine, yellowing of skin or eyes, unusual tiredness, or shortness of breath immediately.,Do not take this medication if you are pregnant or breastfeeding without consulting your doctor.,This medication cures relapsing malaria; complete the full course even if you feel better.
Take with food to improve absorption.,You must be tested for G6PD deficiency before starting this medication.,Report any signs of anemia, dark urine, or yellowing of eyes/skin.,Avoid use during pregnancy or breastfeeding.,Do not drive if you experience dizziness or blurred vision.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KRINTAFEL vs ARAKODA, answered by our medical review team.
KRINTAFEL is a Antimalarial that works by KRINTAFEL (tafenoquine) is an 8-aminoquinoline antimalarial that inhibits parasite growth by interfering with the electron transport chain in the mitochondria of Plasmodium species. It is active against both the erythrocytic and exoerythrocytic stages, including hypnozoites of P. vivax.. ARAKODA is a Antimalarial that works by ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KRINTAFEL and ARAKODA depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KRINTAFEL is: Adults: 200 mg orally as a single dose.. The standard adult dose of ARAKODA is: 400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KRINTAFEL and ARAKODA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KRINTAFEL is classified as Category C. No human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if benefit outweighs risk.. ARAKODA is classified as Category C. FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.